Daymark Health Marks First Year of Value-Based Cancer Care and Eyes Scale-Up

According to a recent LinkedIn post from Daymark Health, the company is marking one year since treating its first patient and reports activity including more than 1,400 in-home appointments, 4,500 phone and video visits, and 70,000 patient touchpoints. The post emphasizes that its care model focuses on proactive, coordinated, accountable cancer care aimed at aligning services around patients rather than billing codes.

The company’s LinkedIn post suggests that its first year has been focused on proving the feasibility of value-based cancer care delivered in the home and virtually. The post also indicates that the next phase will prioritize scaling this model, which could signal a shift toward higher patient volumes, deeper payer and provider partnerships, and potentially greater revenue visibility if execution and reimbursement structures support expansion.

The emphasis on “value-based” arrangements implies Daymark Health is targeting contracts that reward outcomes rather than volume, which may resonate with payers seeking cost containment and better oncology outcomes. If the company can demonstrate reduced hospitalization, improved patient experience, and strong quality metrics at scale, this positioning may enhance its attractiveness to insurers, health systems, and potential strategic investors.

The operational data points in the post hint at a growing base of real-world evidence, which could be leveraged in negotiations with payers and partners. However, the post also acknowledges that value-based cancer care requires new workflows, incentives, and high levels of trust, underscoring execution risk and the need for continued investment in clinical infrastructure, technology, and workforce as the company moves from proof-of-concept to scale.

For the broader oncology and home-based care market, the post reflects ongoing interest in alternative care models that shift complex treatment into lower-cost settings. Should Daymark Health’s approach gain traction and be replicated across markets, it could contribute to competitive pressure on traditional oncology practices while creating opportunities in home health, virtual care platforms, and risk-bearing entities aligned with value-based oncology contracts.